Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
10:49am, Friday, 22'nd Jul 2022 Zacks Investment Research
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.
New Indication Approval For Incyte "To Usher New Growth Avenue"
05:03pm, Thursday, 21'st Jul 2022 Benzinga
JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ: INCY) based on multiple discounted earnings per share and re
HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders
05:01pm, Thursday, 21'st Jul 2022 Benzinga
HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class agent for multiple inflammatory disor
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
02:40pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
What This FDA Delay Means for Novartis
02:15pm, Thursday, 21'st Jul 2022 The Motley Fool
The FDA defers action on a highly anticipated potential blockbuster drug for cancer.
What This FDA Delay Means for Novartis
10:15am, Thursday, 21'st Jul 2022
The FDA defers action on a highly anticipated potential blockbuster drug for cancer.
11 High-Yield Dividend Aristocrats Perfect For The Coming Recession
01:15pm, Wednesday, 20'th Jul 2022 Seeking Alpha
In this article, I discuss about high-yield defensive dividend aristocrats that can help weather the recession. Click here to know them.
Company News for Jul 20, 2022
12:32pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Companies in The News Are: BA, NVS, TFC, IBM
11 High-Yield Dividend Aristocrats Perfect For The Coming Recession
09:15am, Wednesday, 20'th Jul 2022
Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confide
Ford, General Motors Rally; Check These Other Big Gainers From Yesterday
08:51am, Wednesday, 20'th Jul 2022 Benzinga
U.S. stocks closed sharply higher, with the Dow Jones gaining more than 750 points on Tuesday. Here is the list of some big stocks recording gains in the previous session.
Coinbase Global, Inc. (NASD
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
07:59am, Wednesday, 20'th Jul 2022 Benzinga
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings an
Novartis (NVS) Q2 2022 Earnings Call Transcript
09:00pm, Tuesday, 19'th Jul 2022 The Motley Fool
NVS earnings call for the period ending June 30, 2022.
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
04:04pm, Tuesday, 19'th Jul 2022 Benzinga
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue f
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
03:48pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
02:37pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
